Comparative Pharmacology
Head-to-head clinical analysis: BLISOVI FE 1 20 versus TRI SPRINTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLISOVI FE 1 20 versus TRI SPRINTEC.
BLISOVI FE 1/20 vs TRI-SPRINTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol, an estrogen, and desogestrel, a progestin, which inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation and altering cervical mucus and endometrial lining to reduce likelihood of fertilization and implantation.
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
One tablet orally once daily for 21 days, followed by 7 days of placebo (iron-containing) tablets. Each active tablet contains 0.1 mg levonorgestrel and 20 mcg ethinyl estradiol.
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
None Documented
None Documented
Ethinyl estradiol: ~12-14 hours; norethindrone: ~7-8 hours; both allow once-daily dosing with steady-state reached within 7-10 days.
Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days.
Renal: ~50-60% as metabolites; fecal: ~40-50% via biliary elimination; less than 10% unchanged in urine.
Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive